Analyst Price Target is $7.52
▲ +878.61% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Invivyd in the last 3 months. The average price target is $7.52, with a high forecast of $10.00 and a low forecast of $3.55. The average price target represents a 878.61% upside from the last price of $0.77.
Current Consensus is
Buy
The current consensus among 4 polled investment analysts is to buy stock in Invivyd. This rating has held steady since March 2024, when it changed from a Moderate Buy consensus rating.
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Read More
